Decline and Rebound in Routine Cancer Screening Rates During the COVID-19 Pandemic
- PMID: 33742300
- PMCID: PMC7978463
- DOI: 10.1007/s11606-021-06660-5
Decline and Rebound in Routine Cancer Screening Rates During the COVID-19 Pandemic
Conflict of interest statement
Drs. McBain, Cantor, Bavata, and Ms. Pera declare no conflicts of interest. Dr. Jena reports receiving consulting fees unrelated to this work from Pfizer, Hill Rom Services, Bristol Myers Squibb, Novartis, Amgen, Eli Lilly, Vertex Pharmaceuticals, AstraZeneca, Celgene, Tesaro, Sanofi Aventis, Biogen, Precision Health Economics, and Analysis Group. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Figures
Comment in
-
Routine Cancer Screening Rates Rebound After Deep Drop From Pandemic Fear.CA Cancer J Clin. 2021 Sep;71(5):366-368. doi: 10.3322/caac.21692. Epub 2021 Aug 4. CA Cancer J Clin. 2021. PMID: 34347877 Free PMC article. No abstract available.
References
-
- Common Cancer Types - National Cancer Institute [Internet]. 2015 [cited 2020 Aug 21]. Available from: https://www.cancer.gov/types/common-cancers.
-
- Castlight Health. Castlight Health: Health Navigation Platform [Internet]. 2020 [cited 2020 Dec 8]. Available from: https://www.castlighthealth.com/.
-
- IBM Watson Health. The Medical Episode Grouper: Applications and Methodology. [Internet]. IBM; 2018. Available from: https://www.ibm.com/downloads/cas/EZALXAMB. Accessed 1 Nov 2020.
-
- Nelson B. Covid-19 is shattering US cancer care. BMJ [Internet]. 2020 Apr 17 [cited 2020 Dec 1];369. Available from: https://www.bmj.com/content/369/bmj.m1544. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical